Search and Filter
Results per Page:
Dr. Elizabeth Halloran, expert in vaccine trial design and quantitative methods for infectious diseases, transitions to emerita
Infectious disease modeling pioneer helped outline modern precepts for design and analysis of vaccine trials, causal inference with interference; shaped a generation of infectious disease scientists
The benefits of HIV research? Let us count the ways
HIV work has helped shape the FDA, provided drugs for other infections, changed health systems globally and more, say Fred Hutch experts
Viral immunologist taps ‘incredible potential’ of immune system
Dr. Paul Thomas will combine computational and empirical approaches to understand the immune repertoire and turn this knowledge into new diagnostic and therapeutic tools
New horizons in infectious disease treatment and prevention in immunocompromised patients
The 5th Symposium on Infectious Disease in the Immunocompromised Host emphasized new opportunities, next generation
Dr. Peter Gilbert receives Marvin Zelen Leadership Award in Statistical Science
Award recognizes leadership in HIV vaccine trial development, analysis
Managing mountains of genomic data
Tools invented at Fred Hutch are helping researchers analyze the enormous global database of genomic sequences of the virus that causes COVID-19 to better understand how pathogens evolve and spread
Drs. Keith Jerome and Jesse Bloom elected fellows of American Academy of Microbiology
Fred Hutch researchers’ study of viruses evolves from basic understanding to practical applications
With respiratory infections rampant, experts urge masking and vaccination
Limited disease data makes it hard to accurately assess flu trends
50 years of doing hard things
Founded in 1975 to honor a brother, Fred Hutch Cancer Center pursued bold science, pioneered a cure for blood diseases that changed medicine and became a world-class biomedical research and clinical care institution
Starting the year smarter
How patients, providers, researchers and others stay informed amid a deluge of data and information
Crunching the numbers for next-gen COVID-19 vaccines
BARDA taps Fred Hutch biostatisticians to assess new vaccine technology, more nimble trial design
‘Action and progress link our globe’
HVTN’s Dr. Daniel Driffin focused on hope in remarks at White House World AIDS Day event
How protective antibodies get in malaria’s way
Fred Hutch researchers’ structural insights help reveal weak spot in parasite’s mode of attack, could guide vaccine design
Laying the groundwork for a new cancer-preventive vaccine
Fred Hutch scientists garner large NCI award to uncover secrets of immune response to virus behind Kaposi sarcoma
Going straight to the source in defense against infant RSV
New anti-idiotype antibody a first step in possible strategy to build infant immunity during vulnerable window
Infectious disease experts propose trials network dedicated to immunocompromised patients
ImmunOptimize workshop convened stakeholders across disciplines to brainstorm infectious disease clinical trials network designed to serve people with weakened immune systems
Zeroing in on vaginal microbes that most increase HIV risk
Signature combination of BV bacteria and immune proteins associated with highest risk could help guide prevention
Getting a paw up in the cat-and-mouse game with the COVID-19 virus
Fred Hutch researchers invent method to quickly and safely test thousands of mutations to predict which ones could help the virus escape our defenses
New biomarker could one day help tailor immunotherapy for Merkel cell carcinoma
Helps explain why only certain MCC patients respond to immune checkpoint inhibitors, could point toward new strategies to improve treatment responses
Infectious disease scientists look beyond the pandemic
A symposium about protecting people with weakened immune systems from microbial threats